Citations

Showing 10 of 108081 citations.

Mid-term Renal and Mesenteric Artery Outcomes During Fenestrated and Branched Endovascular Aortic Repair for Complex Abdominal and Thoracoabdominal Aortic Aneurysms in the United States Aortic Research Consortium
Tenorio, Emanuel R. , Schanzer, Andres , Timaran, Carlos H. , Schneider, Darren B. , Mendes, Bernardo C. , Eagleton, Matthew J. , Parodi, Federico E., Gasper, Warren J. , Sweet, Matthew P. , Huang, Ying , Tenorio, Emanuel R , Schneider, Darren B , Farber, Mark , Beck, Adam W , Oderich, Gustavo S.

Mayo Clinic

Annals of Surgery | April 13, 2023 | Volume: 278 | Issue: 4 | Pages: e893-e902

10.1097/sla.0000000000005859 | PMID 37051912 Get It

Objective: To report mid-term outcomes of renal-mesenteric target arteries (TAs) after fenestrated-branched endovascular aortic repair (FB-EVAR) of complex abdominal and thoracoabdominal aortic aneurysm. Background: TA instability (TAI) is the most frequent indication for reintervention after FB-EVAR. Methods: Data from consecutive patients enrolled in 9 prospective nonrandomized physician-sponsored investigational device exemption studies between 2005 and 2020 were reviewed. TA outcomes through 5 years of follow-up were analyzed for vessels incorporated by fenestrations or directional branches (DBs), including TA patency, endoleak, integrity failure, reintervention, and instability. Results: A total of 1681 patients had 6349 renal-mesenteric arteries were targeted using 3720 fenestrations (59%), 2435 DBs (38%), and 194 scallops (3%). Mean follow was 23 ± 21 months. At 5 years, TAs incorporated by fenestrations had higher primary (95 ± 1% vs 91 ± 1%, P < 0.001) and secondary patency (98 ± 1% vs 94 ± 1%, P < 0.001), and higher freedom from TAI (87 ± 2% vs 84 ± 2%, P = 0.002) compared with TAs incorporated by DBs, with no differences in other TA events. DBs targeted by balloon-expandable stent-grafts had significantly lower freedom from TAI (78 ± 4% vs 88 ± 1%, P = 0.006), TA endoleak (87 ± 3% vs 97 ± 1%, P < 0.001), and TA reintervention (83 ± 4% vs 95 ± 1%, P < 0.001) compared with those targeted by self-expandable stent-grafts Conclusions: Incorporation of renal and mesenteric TA during FB-EVAR is safe and durable with high 5-year patency rates and low freedom from TAI. DBs have lower patency rates and lower freedom from TAI than fenestrations, with better performance for self-expandable stent grafts as compared with balloon-expandable stent grafts.
Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial ( BESST )
Parkman, Henry P. , Yates, Katherine P. , Sarosiek, Irene , Bulat, Robert, Koch, Kenneth L. , Grover, Madhusudan , Farrugia, Gianrico , Silver, Paul J., Abdullah, Amirah, Maurer, Alan H. , Malik, Zubair , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , McCallum, Richard W. , Grover, Madhusudan , Farrugia, Gianrico , Parkman, H P , Abell, Thomas L. , Kuo, Braden , Silver, Paul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 13, 2023 | Volume: 57 | Issue: 11 | Pages: 1272-1289

10.1111/apt.17479 | PMID 37052334 Get It

Summary Background Patients with gastroparesis and related disorders have symptoms including early satiety, postprandial fullness and bloating. Buspirone, a 5‐HT 1 receptor agonist, may improve fundic accommodation. Aim To determine if buspirone treatment improves early satiety and postprandial fullness in patients with symptoms of gastroparesis. Methods This 4‐week multi‐centre clinical trial randomised patients with symptoms of gastroparesis and moderate‐to‐severe symptoms of fullness (Gastroparesis Cardinal Symptom Index [GCSI] early satiety/postprandial fullness subscore [ES/PPF]) to buspirone (10 mg orally) or placebo three times per day. The primary outcome was a change in the ES/PPF from baseline to 4 weeks. The primary analysis was per protocol intention‐to‐treat ANCOVA of between‐group baseline vs. 4‐week differences (DoD) in ES/PPF adjusted for baseline ES/PPF. Results are reported using both nominal and Bonferroni (BF) p values. Results and conclusions Ninety‐six patients (47 buspirone, 49 placeboes; 92% female, 50% delayed gastric emptying, 39% diabetic) were enrolled. There was no between‐groups difference in the 4‐week ES/PPF primary outcome: −1.16 ± 1.25 (SD) on buspirone vs −1.03 ± 1.29 (SD) on placebo (mean DoD: −0.11 [95% CI: −0.68, 0.45]; p = 0.69). Buspirone performed better than placebo in patients with severe‐to‐very severe bloating at baseline compared to patients with none to moderate: (ES/PPF DoD = −0.65 vs. 1.58, p TX*GROUP = 0.003; p BF = 0.07). Among individual GCSI symptoms, only bloating appeared to improve with buspirone vs. placebo. Conclusions Patients with moderate‐to‐severe early satiety/postprandial fullness and other symptoms of gastroparesis did not benefit from buspirone treatment to improve the ES/PPF primary outcome compared with placebo. There was a suggestion of the benefit of buspirone in patients with more severe bloating. Trial Registration: ClinicalTrials.gov NCT0358714285.
Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience
Gregory, Timothy A. , Mastall, Max , Lin, Heather , Hess, Kenneth R. , Yuan, Ying , García, Manuela Martín-Bejarano , Alfaro, Kristin D, Gule-Monroe, Maria , Khatua, Soumen , Rao, Ganesh , Sandberg, David I. , Yeboa, D.N. , McGovern, Susan L. , Zaky, Wafik , Mahajan, Anita , Suki, Dima , Weathers, Shiao‐Pei , Puduvalli, Vinay K. , Peñas-Prado, Marta , Majd, Nazanin , Puduvalli, Vinay K , Fuller, Gregory N. , Huse, Jason T. , Wefel, Jeffrey S. , Paulino, Arnold C. , Harrison, Rebecca A , Groot, John de

Mayo Clinic

Neuro-Oncology Advances | April 13, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdad032 | PMID 37114244 Get It

Abstract Background Medulloblastoma in adults is rare and treatment decisions are largely driven from pediatric literature. We sought to characterize recurrent medulloblastoma in adults. Methods From a single-institution dataset of 200 adult patients diagnosed with medulloblastoma during 1978–2017, those with recurrence were analyzed for clinical features, treatment, and outcome. Results Of the 200 patients, 82 (41%) with median age of 29 years (18–59) had recurrence after a median follow-up time of 8.4 years (95% CI = 7.1, 10.3). Of these, 30 (37%) were standard-risk, 31 (38%) were high-risk, and 21 (26%) had unknown-risk diseases at the time of initial diagnosis. Forty-eight (58%) presented with recurrence outside the posterior fossa, of whom 35 (43%) had distant recurrence only. Median Progression-free survival (PFS) and OS from initial surgery were 33.5 and 62.4 months, respectively. Neither PFS nor OS from initial diagnosis differed between the standard-risk and high-risk groups in those who experience recurrence (P = .505 and .463, respectively). Median OS from first recurrence was 20.3 months, also with no difference between the standard-risk and high-risk groups (P = .518). Recurrences were treated with combinations of re-resection (20 patients; 25%), systemic chemotherapy (61 patients; 76%), radiation (29 patients; 36%), stem cell transplant (6 patients; 8%), and intrathecal chemotherapy (4 patients; 5%). Patients who received radiation at recurrence had better OS (32.9 months) than those who did not (19.2 months) (P = .034). Conclusions Recurrent medulloblastoma in adults has a poor prognosis irrespective of initial risk stratification. Recurrence commonly arises outside the posterior fossa years after initial diagnosis.
Clinical features and outcomes of high grade serous ovarian cancer (HGSOC) in Asian Indians and Pakistani Americans (AIPA)
Gaire, Suman , Budhathoki, Pravash , Shah, Anish , Karki, Ujjwal , Yadav, Siddhartha

Mayo Clinic

International Journal of Cancer Care and Delivery | April 13, 2023 | Volume: 3 | Issue: Supplement 1 | Pages: No page available

10.53876/001c.73636 Get It

Mycolactone: A Broad Spectrum Multitarget Antiviral Active in the Picomolar Range for COVID-19 Prevention and Cure
Asiedu, Seth O. , Gupta, Yash , Nicolaescu, Vlad , Gula, Haley , Caulfield, Thomas R. , Durvasula, Ravi , Kempaiah, Prakasha , Kwofie, Samuel K., Wilson, Michael D. , Asiedu, Seth Osei , Kwofie, Samuel K , Caulfield, Thomas R , Kempaiah, Prakasha , Gupta, Yash

Mayo Clinic

International Journal of Molecular Sciences | April 13, 2023 | Volume: 24 | Issue: 8 | Pages: 7151

10.3390/ijms24087151 | PMID 37108313 Get It

We have previously shown computationally that Mycolactone (MLN), a toxin produced by Mycobacterium ulcerans, strongly binds to Munc18b and other proteins, presumably blocking degranulation and exocytosis of blood platelets and mast cells. We investigated the effect of MLN on endocytosis using similar approaches, and it bound strongly to the N-terminal of the clathrin protein and a novel SARS-CoV-2 fusion protein. Experimentally, we found 100% inhibition up to 60 nM and 84% average inhibition at 30 nM in SARS-CoV-2 live viral assays. MLN was also 10× more potent than remdesivir and molnupiravir. MLN’s toxicity against human alveolar cell line A549, immortalized human fetal renal cell line HEK293, and human hepatoma cell line Huh7.1 were 17.12%, 40.30%, and 36.25%, respectively. The cytotoxicity IC50 breakpoint ratio versus anti-SARS-CoV-2 activity was more than 65-fold. The IC50 values against the alpha, delta, and Omicron variants were all below 0.020 µM, and 134.6 nM of MLN had 100% inhibition in an entry and spread assays. MLN is eclectic in its actions through its binding to Sec61, AT2R, and the novel fusion protein, making it a good drug candidate for treating and preventing COVID-19 and other similarly transmitted enveloped viruses and pathogens.
BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia
Chohan, Karan , Kapoor, Prashant , Chohan, Karan L

Mayo Clinic

Hemato | April 13, 2023 | Volume: 4 | Issue: 2 | Pages: 135-157

10.3390/hemato4020012 Get It

Waldenström macroglobulinemia (WM) is a rare, non-Hodgkin lymphoma that remains incurable. Rituximab, an anti-CD20 monoclonal antibody has been the cornerstone of treatment against WM, and its combination with an alkylator, bendamustine, achieves durable remission in treatment-naive patients with symptomatic WM. However, novel “druggable” targets that have been identified within the clonal lymphoplasmacytic cells in WM have resulted in a rapid development of targeted therapies in both the frontline and relapsed and refractory (R/R) settings. Several agents directed against the known targets have shown promising efficacy, with mostly manageable toxicities. The class of Bruton’s tyrosine kinase (BTK) inhibitors has transformed the therapeutic landscape for patients with WM, given their convenient oral dosing and strong efficacy, with high rates of attainment of very good partial response (VGPR). The tolerability of the next-generation BTK inhibitors appears to be superior to that of the first-in-class agent, ibrutinib. Targeted therapies from other classes have also demonstrated efficacy in both single-agent and combination regimens. Inhibitors of proteasome BCL-2, mTOR and PI-3 kinase have demonstrated efficacy in WM. Emerging therapies under investigation will continue to further shape the management paradigm, especially in the R/R setting. These include bispecific antibodies, radiotherapeutic agents and chimeric antigen receptor T-cell (CART) cell therapies. This review outlines the current literature and future direction of targeted therapies in WM.
Lessons learned from conducting the first cancer care delivery trial in the Alliance for Clinical Trials in Oncology (Alliance A191402CD)
Pacyna, Joel E. , Dueck, Amylou C. , Chang, George J. , Chow, Selina , Tilburt, Jon C. , Dueck, A. C. , Paskett, Electra D. , Kim, Simon

Mayo Clinic

Clinical Trials | April 13, 2023 | Volume: 20 | Issue: 5 | Pages: 559-563

10.1177/17407745231167123 | PMID 37050880 Get It

Introduction: Testing healthcare delivery interventions in rigorous clinical trials is a critical step in improving patient care, but conducting multisite randomized clinical trials to test the effect of care delivery interventions has unique challenges and requires foresight and planning. Methods: We conducted the first care delivery trial (A191402CD) in the Alliance for Clinical Trials in Oncology, a National Cancer Institute Community Oncology Research Program research base, which tested the effectiveness of two different decision aids for supporting shared decision-making about prostate cancer treatment. Our experience illustrates the kind of challenges that confront care delivery researchers as they seek to test interventions to improve the experiences of patients. Results: Lessons learned include the following: cluster-randomized designs introduce complexity; workflow disruption can discourage site participation; evidence-based methods may not always be sufficient. Conclusion: We conclude with the following recommendations: assessing feasibility requires special rigor; relationships and interpersonal dynamics must be leveraged. Our experiences may inform future care delivery research.
EZH2 and POU2F3 Can Aid in the Distinction of Thymic Carcinoma from Thymoma
Vrana, Julie A. , Koepplin, Justin W. , Molina, Julian R. , Roden, Anja C. , Naso, Julia R, Naso, Julia

Mayo Clinic

Cancers | April 13, 2023 | Volume: 15 | Issue: 8 | Pages: 2274

10.3390/cancers15082274 | PMID 37190202 Get It

Thymic carcinoma is an aggressive malignancy that can be challenging to distinguish from thymoma using histomorphology. We assessed two emerging markers for these entities, EZH2 and POU2F3, and compared them with conventional immunostains. Whole slide sections of 37 thymic carcinomas, 23 type A thymomas, 13 type B3 thymomas, and 8 micronodular thymomas with lymphoid stroma (MNTLS) were immunostained for EZH2, POU2F3, CD117, CD5, TdT, BAP1, and MTAP. POU2F3 (≥10% hotspot staining), CD117, and CD5 showed 100% specificity for thymic carcinoma versus thymoma with 51%, 86%, and 35% sensitivity, respectively, for thymic carcinoma. All POU2F3 positive cases were also positive for CD117. All thymic carcinomas showed >10% EZH2 staining. EZH2 (≥80% staining) had a sensitivity of 81% for thymic carcinoma and a specificity of 100% for thymic carcinoma versus type A thymoma and MNTLS but had poor specificity (46%) for thymic carcinoma versus B3 thymoma. Adding EZH2 to a panel of CD117, TdT, BAP1, and MTAP increased cases with informative results from 67/81 (83%) to 77/81 (95%). Overall, absent EZH2 staining may be useful for excluding thymic carcinoma, diffuse EZH2 staining may help to exclude type A thymoma and MNTLS, and ≥10% POU2F3 staining has excellent specificity for thymic carcinoma versus thymoma.
What Are the Functions of the Superior Colliculus and Its Involvement in Neurologic Disorders?
Benarroch, Eduardo E.

Mayo Clinic

Neurology | April 13, 2023 | Volume: 100 | Issue: 16 | Pages: 784-790

10.1212/wnl.0000000000207254 | PMID 37068960 Get It

Incidence and risk of herpes zoster in patients with ulcerative colitis and Crohn’s disease in the USA
Singer, David , Thompson‐Leduc, Philippe , Gupta, Deepshekhar , Cheng, Wendy Y. , Poston, Sara , Ma, Siyu , Pawlowski, John E. , Duh, Mei Sheng , Morris, Eric , Devine, Francesca , Morris, Eric D , Farraye, Francis A , Farraye, Francis A.

Mayo Clinic

Gastroenterology Report | April 12, 2023 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1093/gastro/goad016 | PMID 37064550 Get It

AbstractBackgroundPatients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ). We evaluated the incidence of HZ in ulcerative colitis (UC) and Crohn’s disease (CD) patients and compared this with HZ incidence in a non-IBD population.MethodsWe conducted a retrospective cohort study (GSK study identifier: VEO-000043) of adults aged ≥18 years with UC and CD and without IBD who were identified from claims recorded in a US healthcare database between October 2015 and February 2020. Crude HZ incidence rates/1,000 person-years (PY) were calculated, and comparisons of HZ incidence rates between UC or CD and non-IBD cohorts were made using adjusted generalized linear models.ResultsThe study population comprised a total of 29,928 UC, 25,959 CD, and 11,839,329 non-IBD patients. Crude overall HZ incidence rates were 13.64/1,000 PY (UC), 15.94/1,000 PY (CD), and 7.95/1,000 PY (non-IBD). UC and CD patients had increased HZ incidence rates, with adjusted incidence rate ratios of 1.35 (95% confidence interval [CI], 1.26–1.44) and 1.66 (95% CI, 1.56–1.77), respectively, compared with non-IBD patients. Stratified analysis indicated increased relative rates of HZ in progressively younger age strata in the UC and CD patients compared with non-IBD patients. HZ incidence rates were higher in UC and CD patients who had previously received thiopurines or methotrexate, TNF-inhibitors, or corticosteroids than in UC and CD patients who did not take those medicines.ConclusionUC and CD patients had increased HZ incidence rates compared with patients without IBD, demonstrating the importance of HZ prevention in IBD patients.